Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCC-3116 combination study in advanced KIT exon 11-mutant GIST
NL-OMON59448Phase 2Suspended
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of inlexisertib in gastrointestinal stromal tumor (GIST), sponsored by Deciphera Pharmaceuticals. Started Mar 2026; status: suspended.
02
Drugs
inlexisertib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NL-OMON59448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59448.